Introduction
============

Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disorder that can have detrimental and sometimes devastating effects on patients and their families. APS may involve essentially any circulatory bed in the body. While the deep veins of the lower limbs and the arterial circulation of the brain are the most common sites of thrombosis, any tissue or organ can be affected.^\[[@R1],[@R2]\]^ Obstetrical complications are also well recognized in APS, including eclampsia or severe preeclampsia that results in premature birth, as well as fetal demise after the 10th week of gestation.^\[[@R1],[@R3]\]^ Beyond thrombosis and pregnancy complications, other clinical features such as persistent thrombocytopenia, hemolytic anemia, livedo reticularis, APS nephropathy, and cognitive dysfunction have been associated with APS, are clearly associated with APS and often referred to as "non-criteria" or "extra-criteria" manifestations^\[[@R4]\]^ \[Table [1](#T1){ref-type="table"}\]. APS is divided into primary APS that occurs in isolation, and secondary APS that is associated with another autoimmune syndrome, most commonly systemic lupus erythematosus (SLE). Catastrophic antiphospholipid syndrome (CAPS), which is characterized by thrombi in multiple small vascular beds leading to multi-organ failure with high mortality, develops in a small subgroup of APS patients.^\[[@R5]\]^ The estimated population prevalence of APS is 50 cases per 100,000, with an annual incidence of 2.1 per 100,000.^\[[@R6]\]^ Observational studies, which typically lack rigorous follow-up, have shown that antiphospholipid antibodies (aPL) may be positive in as many as 13% of patients with stroke, 11% with myocardial infarction, and 9.5% of patients with deep vein thrombosis.^\[[@R7]\]^ The prevalence of persistently positive aPL among the healthy population is still not known.

###### 

Clinical manifestations of antiphospholipid syndrome.
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Classification of APS requires a positive test of one or more typical aPL (anticardiolipin \[aCL\] IgG or IgM, anti-β2glycoprotein-I \[aβ2GPI\] IgG or IgM, and lupus anticoagulant \[LA\]) in the context of either a thrombotic event or certain types of pregnancy morbidity \[Table [2](#T2){ref-type="table"}\].^\[[@R8]\]^ However, in daily practice APS may be much more complex and clearly represents a disease spectrum \[Figure [1](#F1){ref-type="fig"}\]. While there are some APS patients with seemingly isolated thrombotic or obstetric complications, there are also patients who have persistently positive aPL and only "non-criteria" manifestations. There are also a small group of patients who develop CAPS. We will now review current literature relevant to APS clinical care and briefly describe some updates related to pathophysiology.

###### 

Classification criteria for antiphospholipid syndrome.
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![Overlapping clinical spectrum of antiphospholipid syndrome (APS). aPL: Antiphospholipid antibodies; CAPS: Catastrophic antiphospholipid syndrome.](cm9-133-0929-g003){#F1}

Update on pathophysiology
=========================

Antiphospholipid antibodies (aPL) are a heterogeneous group of autoantibodies that play an important role in the pathogenesis of APS via their interactions with plasma protein such as β2-glycoprotein I (β2GPI), prothrombin, thrombomodulin, plasminogen, antithrombin III, protein C, protein S, annexin II, and annexin V.^\[[@R9]--[@R14]\]^ Key aPL-mediated prothrombotic mechanisms involve the activation of endothelial cells,^\[[@R15]\]^ monocytes,^\[[@R16]\]^ platelets,^\[[@R17]\]^ coagulation factors, and complement proteins.^\[[@R18],[@R19]\]^ Furthermore, aPL interfere with fibrinolytic and coagulation pathways and trigger placental inflammation and injury.^\[[@R20],[@R21]\]^ As the pathogenesis of APS has been reviewed in detail elsewhere,^\[[@R22],[@R23]\]^ we will here just highlight a few recent studies that may advance our understanding of APS pathogenesis.

MicroRNAs (miRNAs) are single-stranded small non-coding RNAs that play an important role in cellular communication. They act to regulate the expression of messenger RNAs which contain complementary sequence to miRNAs. In recent years, several groups have characterized miRNAs in the pathogenesis of APS.^\[[@R24]--[@R27]\]^ One interesting study found that forced overexpression of certain miRNAs (miR-19b and miR-20a) in tissue factor-expressing cell lines reduced levels of tissue factor messenger RNA, along with cellular procoagulant activity.^\[[@R25]\]^ It appears that monocytes from APS patients have significantly lower levels of miR-19b and miR-20a as compared with healthy controls, with low levels of these miRNAs predicting an increased level of tissue factor.^\[[@R25]\]^ In a different study, *in vitro* treatment of healthy-donor neutrophils, monocytes, and endothelial cells with purified aPL IgG decreased the expression of various miRNAs.^\[[@R27]\]^ At the same time, differential expression of circulating miRNAs can distinguish APS patients from healthy controls^\[[@R26]\]^; for example, transcriptomic analysis of plasmacytoid dendritic cells from APS and SLE patients suggested that lower miRNA expression (miR-361-5p, miR-128-3p, miR-181a-2-3p, and others) associates with a heightened type I interferon signature.^\[[@R24]\]^ More studies are needed to further elucidate the role that miRNAs play in APS disease modulation, and the extent to which miRNAs may be viable therapeutic targets.

Many studies from the general thrombosis literature have revealed that activated neutrophils, and in particular neutrophil extracellular trap (NET) formation, contribute to the propagation of thrombi affecting arterial, venous, and microscopic vascular beds.^\[[@R28],[@R29]\]^ NETs have also been recently implicated in the pathogenesis of APS. In 2015, our group reported that sera from APS patients, as well as purified aPL, trigger neutrophils to release NETs.^\[[@R30]\]^ The potential *in vivo* relevance of this observation has been confirmed in mouse models of aPL-mediated large-vein thrombosis in which either depletion of neutrophils or digestion of NETs is protective.^\[[@R31]\]^ Neutrophils from APS patients also appear to have increased adhesive potential, which is dependent upon the activated form of integrin Mac-1. This proadhesive phenotype amplifies neutrophil-endothelium interactions, potentiates NET formation, and potentially lowers the threshold for thrombosis.^\[[@R32]\]^

Sera from primary APS patients have elevated type I interferon activity,^\[[@R33]\]^ which has been confirmed by many groups.^\[[@R34]--[@R36]\]^ Interestingly, transcriptome analysis of neutrophils from APS patients revealed a heightened expression of genes relevant to not only interferon signaling, but also cellular defense and cell-cell adhesion. One particular gene encoding P-selectin glycoprotein ligand-1 (PSGL-1) was strongly upregulated and potentially involved in thrombus formation. Indeed, an *in vivo* model demonstrated that PSGL-1 deficiency protected mice from aPL-accelerated thrombus formation.^\[[@R37]\]^ The relevance of this pathway in patients has yet to be intensively studied.

Therapies that target NET formation have the potential to treat thrombotic diseases.^\[[@R29]\]^ For example, selective agonism of the adenosine A2A receptor suppresses aPL-mediated NETosis in protein kinase A-dependent fashion.^\[[@R38]\]^ A2A agonism also reduces thrombosis in the inferior vena cava of both control mice and mice treated with aPL. Dipyridamole, which is known to potentiate adenosine signaling by increasing extracellular concentrations of adenosine and interfering with the breakdown of cAMP, also suppresses aPL-mediated NETosis and mitigates venous thrombosis in mice. Interestingly, CD39 and CD73, which convert extracellular ATP first to AMP and then to adenosine protect experimental animals from aPL-induced fetal loss.^\[[@R39]\]^

In summary, it is likely that heterogeneous mechanisms are at play in the prothrombotic and proinflammatory mechanisms mediated by aPL. Emerging role of miRNAs in APS pathogenesis has attracted growing attention. Neutrophils and NET formation have only recently been investigated, and future research should help us understand the extent to which neutrophils are viable drug targets in patients with APS, as well as how neutrophils interact with other well-accepted players in APS pathophysiology such as endothelial cells and platelets. We speculate that therapies targeting NETs may hold particular promise, at least for a subset of patients with APS.

Primary thrombosis prophylaxis
==============================

One of the most significant challenges in APS management is the treatment strategy for asymptomatic aPL-positive individuals. It is well known that persistently positive aPL are associated with an increased risk of arterial and venous thrombosis.^\[[@R40]\]^ However, precise quantification of such risk has been difficult due to inconsistent application of aPL laboratory criteria, the multifactorial nature of thrombosis risk, and various confounding factors such as underlying autoimmune diseases and medication effects.^\[[@R40],[@R41]\]^ Routine primary thrombosis prophylaxis among asymptomatic aPL carriers remains controversial due to limited and low quality data.^\[[@R41],[@R42]\]^ Here we will summarize current evidence and recommendations regarding primary thrombosis prophylaxis as it relates to APS.

Clinically-significant aPL
--------------------------

The first step in risk stratifying an aPL-positive individual is to determine whether a positive aPL test is clinically significant.^\[[@R40]\]^ Transiently positive aPL are common, especially during concomitant infections, and are often not associated with thrombosis. A recent systemic review of 297 infection-associated aPL-positive cases (24.6% fulfilled full Sydney classification criteria) showed that 75.4% of positive aPL detected during an infection are transient.^\[[@R43]\]^ A prospective cohort study of blood samples from healthy donors showed 10% baseline positivity for aCL or LA; however, 12 months later only 1% of those blood samples remained positive for aCL or LA.^\[[@R44]\]^ Determination of whether positive aPL are clinically significant should follow the laboratory criteria in the 2006 revised APS classification criteria.^\[[@R8]\]^ First, a positive aPL needs to be at moderate/high titer, which can be defined as greater than the 99th percentile cut-off derived from samples obtained from healthy controls. Second, a positive aPL should be persistently present for at least 12 weeks. Lupus anticoagulant testing should be based on the International Society of Thrombosis and Hemostasis (ISTH) recommendations.^\[[@R45]\]^ While "criteria aPL" (IgG/IgM of aCL, IgG/IgM of aβ~2~GPI, and LA) are the most tested and easily assessable in all clinical settings,^\[[@R46]\]^ there are also a number of non-criteria aPL (eg, anti-phosphatidylserine/ prothrombin (anti-PS/PT), anti-domain I aβ2GPI, IgA isotypes of aCL and aβ2GPI, and APhL) which were discovered in the past 20 years and are not part of the revised APS classification criteria.^\[[@R46]\]^ Presently, these are mainly used in research settings and are not readily available for most practitioners. A report from the 15th International Congress on Antiphospholipid Antibodies Task Force summarized the recent clinical evaluations of various non-criteria aPL.^\[[@R47]\]^ While some of these antibodies did show promising clinical utility in identifying APS patients,^\[[@R47]\]^ more data are needed before recommending them for routine testing. Our opinion is that a number of these tests (such as high-titer presence of anti-PS/PT and anti-domain I aβ2GPI) are potential drivers of APS pathogenesis in at least a subset of APS patients and look forward to future multicenter studies that will evaluate their significance.

Thrombosis incidence of aPL positive carriers
---------------------------------------------

The triggers of thrombosis are likely multifactorial. The absolute thrombosis incidence among asymptomatic aPL-positive carriers is therefore difficult to assess as it is affected by various confounders, both known (eg, age, underlying systemic autoimmune disease, cardiovascular risk factors, traditional venous thrombosis risks, medications) and unknown.^\[[@R48]\]^ Available studies are limited by small sample sizes and study designs that do not always control for these various confounders. For example, a prospective study of 178 asymptomatic aPL carriers without any primary prophylaxis did not observe any thrombotic events during 36 months of follow up.^\[[@R49]\]^ Another prospective 4-year observation of 258 asymptomatic patients with confirmed persistent aPL (54.3% on primary prophylaxis) showed a thrombotic incidence rate of 1.86%.^\[[@R50]\]^ Pengo *et al*^\[[@R51]\]^ conducted a prospective observation of 179 asymptomatic isolated persistent LA carriers (23% on primary prophylaxis) with a total follow up of 552 patient-years. 66% of patients did not have any underlying systemic autoimmune diseases. The observed annual incidence rate of thrombosis was 1.3%. Another prospective observation of 104 triple-positive aPL carriers (63.5% on primary prophylaxis and 47% with an underlying systemic autoimmune disease) with a mean follow up of 4.5 years showed a thrombosis incidence of 5.3%. None of the studies were designed to control for primary prophylaxis use. In summary, thrombosis is multifactorial and the absolute thrombosis incidence among asymptomatic aPL carriers is challenging to assess. Having said that, triple-positive aPL carriers may have a higher annual thrombosis risk. Some experts in the field have suggested that the absolute annual thrombosis incidence in aPL carriers without any other thrombosis risks is less than 1%.^\[[@R48]\]^

Aspirin
-------

Aspirin\'s role as a primary thrombosis prophylactic agent among patients with persistently positive aPL remains debatable.^\[[@R41],[@R42]\]^ APLASA is the only randomized controlled trial (RCT) evaluating the effectiveness of aspirin (*n* = 48) *vs.* placebo (*n* = 50) at preventing first thrombotic event among asymptomatic persistently aPL positive carriers. It concluded that daily low dose aspirin (LDA) (81 mg) is no better than placebo at preventing thrombosis (hazard ratio \[HR\] = 1.04. 95% confidence interval \[CI\]: 0.69--1.56),^\[[@R52]\]^ albeit with a low event rate as a major limitation of this trial. Thus, many experts argue that it is underpowered to detect any effect of LDA. Data from observational studies do suggest a protective effect of aspirin.^\[[@R53]--[@R55]\]^ One such observation of 103 aPL carriers with a mean follow up of 64 months supported the use of LDA as primary thrombosis prophylaxis, particularly in those with either SLE or thrombocytopenia.^\[[@R55]\]^ A recent Cochrane systematic review assessed the effects of antiplatelet or anticoagulant agents *vs*. placebo at preventing thrombosis among aPL-positive individuals. It included nine studies and 1044 participants, and concluded that there is not sufficient evidence to support the use of aspirin for primary thrombosis prevention among asymptomatic aPL carriers.^\[[@R56]\]^ The 15th International Congress on Antiphospholipid Antibodies recognized that we do not yet have convincing evidence to support the use of aspirin in all patients with persistent aPL; however, a subgroup of patients with concomitant cardiovascular disease risks may benefit from LDA to prevent first thrombosis.^\[[@R42]\]^ Recently published EULAR APS treatment recommendations do endorse the use of LDA for primary prophylaxis among patients with high-risk aPL profiles (persistently positive LA, double- and triple-positive aPL).

It must be remembered that even LDA use is associated with increased risk of bleeding. Data from cardiovascular disease prevention studies (albeit with much older participants than many aPL/APS patients) has suggested that chronic LDA use is associated with increased risk of major gastrointestinal bleeding (OR = 1.58, 95% CI: 1.29--1.95.) and hemorrhagic stroke (OR = 1.27, 95% CI: 0.96--1.68).^\[[@R57]\]^ Another recent population-based 10-year observation of 3166 patients who were on LDA (75 mg daily)^\[[@R58]\]^ suggests that the average annual risk of bleeding among patients on aspirin is 3.36%. This annual bleeding risk increases with age, reaching 4.1% at age 85 or older.^\[[@R58]\]^ The risk of bleeding needs to be weighed against the risk of thrombosis when considering LDA as a primary prophylactic agent.

In summary, convincing evidence to support the use of aspirin for primary thrombosis prophylaxis remains lacking, especially for patients without other systemic autoimmune diseases. Persistent aPL carriers with concomitant cardiovascular disease risks, high-risk aPL profiles, or SLE may benefit from aspirin to lower the risk of first thrombosis. The risk of bleeding from aspirin should always be considered when making a decision about primary thrombosis prophylaxis.

Hydroxychloroquine
------------------

Hydroxychloroquine (HCQ) is an important disease-modifying agent for the treatment of systemic autoimmune diseases, particularly SLE. In animal models of APS, treatment with HCQ leads to smaller thrombi and less durable persistence.^\[[@R59]\]^ HCQ may also mediate a reduction of aPL-β2GPI complex binding to phospholipid bilayers and human monocytes.^\[[@R60]\]^ Annexin A5 is an anticoagulant protein that coats phospholipid bilayers and shields them from critical coagulation enzymatic reactions. An *in vitro* study showed that HCQ treatment can attenuate aPL-mediated disruption of the Annexin A5 shield and thereby conserve its anticoagulant properties.^\[[@R61]\]^ An interesting human study showed that higher type I interferon signature was observed in monocytes from APS patients who were not on HCQ as compared with those who were.^\[[@R38]\]^ A prospective follow up of 144 SLE patients with aPL and 144 sex- and age-matched SLE patients without aPL showed that HCQ use is protective against thrombosis in SLE patients with and without aPL.^\[[@R54]\]^ Unfortunately, an international, prospective, RCT of HCQ for primary thrombosis prevention in persistently aPL-positive carriers (without SLE) was terminated recently due to low recruitment rate and high cost.^\[[@R62]\]^ However, before termination, a total of 20 patients with persistently positive aPL without history of thrombosis were enrolled. Nine patients were randomized to receive HCQ and 11 patients did not receive HCQ. None of the patients in either group developed thrombosis during the 1.7 year follow up.^\[[@R62]\]^ Chronic HCQ usage (\>5 years) at higher doses (\>6.5 mg/kg/day or \>1000-g cumulative dose) is associated with an increased risk (1%) of retinal toxicity.^\[[@R63]\]^ Thus, routine ophthalmological surveillance is warranted among patients who are on long term HCQ.

In summary, mechanistic studies do suggest a potentially protective role of HCQ against thrombosis. HCQ reduces thrombosis risk among aPL-positive SLE patients. No completed studies have yet evaluated its role in primary aPL carriers. HCQ must be considered in aPL carriers with underlying systemic autoimmune diseases.

Statins
-------

Statins, which function as 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, have been widely used for primary and secondary cardiovascular disease prevention due to their cholesterol lowering, anti-inflammatory, and anti-thrombotic effects.^\[[@R64]\]^ Fluvastatin-treated APS mice have significantly smaller thrombi, decreased inflammatory molecules (intercellular cell adhesion molecule \[ICAM\]-1), and reduced leukocyte adhesion to endothelial cells compared with controls.^\[[@R65]\]^ Monocytes from 42 thrombotic APS patients treated with 1 month of fluvastatin showed a significant inhibition of tissue factor expression in monocytes.^\[[@R66]\]^ A prospective study of 41 aPL-positive individuals who were treated with 40 mg daily of fluvastatin for 3 months showed significantly reduced circulating proinflammatory and prothrombotic biomarkers post treatment.^\[[@R67]\]^ At this time, there is no randomized clinical trial of statins for primary thrombosis prevention among aPL-positive carriers.

In summary, animal and human mechanistic studies suggest that statin-induced alternation of aPL effects on target cells may be a useful strategy for primary thrombosis prophylaxis and warrants further clinical evaluation. aPL carriers who also have other concomitant cardiovascular disease risk factors may be good candidates for statin medications \[Table [3](#T3){ref-type="table"}\].

###### 

Summary of important clinical studies for primary thrombosis prophylaxis among aPL positive carriers.
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Secondary thrombosis prophylaxis
================================

Secondary thrombosis prophylaxis refers to the treatment of APS patients after an unprovoked arterial and/or venous thrombotic event. Unprovoked thrombotic events are defined as clotting events that are independent from any major transient thrombotic risks such as the usage of estrogen-containing oral contraception, prolonged immobilization, or cancer.^\[[@R2],[@R68]\]^ The current mainstay of treatment for secondary thrombotic prophylaxis is life-long anticoagulation with a vitamin K antagonist, or occasionally low-molecular-weight heparin (LMWH) for patients who have a contraindication to or do not tolerate vitamin K antagonist. Recently, direct oral anticoagulants (DOACs) have been evaluated as an alternative agent for secondary thrombosis prophylaxis among APS patients.

Vitamin K antagonists
---------------------

Vitamin K antagonists such as warfarin have historically been the primary treatment for thrombotic APS. Their efficacy in preventing recurrent thrombosis has been supported by multiple studies. One systemic review suggested that anticoagulation with moderate intensity warfarin (INR between 2.0 and 3.0) reduced the risk of recurrent venous thrombosis by 80% to 90%.^\[[@R69]\]^ Substantial debate has surrounded the intensity of vitamin K antagonist therapy in patients with APS. Several early observation studies suggested that optimal anticoagulation regimens were those that maintained the INR between 3.0 and 4.0.^\[[@R70]--[@R72]\]^ However, two randomized controlled trials in 2000s suggested otherwise. A randomized, double-blind trial of 114 APS patients in which patients were assigned to receive vitamin K antagonist to achieve an INR of 2.0 to 3.0 (moderate intensity) or 3.1 to 4.0 (high intensity), showed that high-intensity vitamin K antagonist was not superior to moderate-intensity for secondary thromboprophylaxis.^\[[@R73]\]^ A second trial of 109 patients confirmed that high-intensity vitamin K antagonist therapy was not superior to standard treatment in preventing recurrent thrombosis in patients with APS and was associated with an increased rate of hemorrhagic complications.^\[[@R74]\]^ Based on the evidence of the above two trials, the current standard of care for initial management of thrombotic APS is moderate-intensity vitamin K antagonist. Critics of those two trials argue that the proportion of participants persistently achieved the higher INR target was low and very few APS patients with arterial thrombosis were enrolled. Many experts in the field continue to endorse the use of high-intensity vitamin K antagonist among APS patients with recurrent thrombosis based on anecdotal data and personal experience. Though evidence is limited, recent EULAR APS management guideline considers high-intensity vitamin K antagonist as an alternative option to LMWH for APS patients with recurrent thrombosis.^\[[@R75]\]^ A final point is that, in many centers, LDA is combined with a vitamin K antagonist for secondary prevention in patients with arterial thromboembolic events and one recent retrospective observation supports combination therapy.^\[[@R76]\]^

Direct oral anti-coagulants (DOACs)
-----------------------------------

Oral direct thrombin or direct factor Xa inhibitors such as rivaroxaban or apixaban have recently received widespread use for thrombosis prevention among patients with atrial fibrillation and those receiving hip or knee replacement, as well as for treatment of deep venous thrombosis.^\[[@R77]\]^ Retrospective observations have reported on DOAC use for secondary thrombosis prophylaxis among APS patients and have demonstrated conflicting results regarding its efficacy.^\[[@R78]\]^ Three randomized controlled trials to date have evaluated the effectiveness of DOAC for secondary thrombosis prophylaxis among APS patients. The first study was an open-label randomized controlled non-inferiority study of 166 (28% triple positive) APS patients comparing rivaroxaban with warfarin. The primary outcome was not clinical, but rather the percentage change in endogenous thrombin potential (ETP) from randomization to day 42, with non-inferiority set at less than 20% difference from the warfarin treatment arm.^\[[@R79]\]^ The result of this study did not meet its primary endpoint, which was the set non-inferiority threshold. Importantly, no thrombosis or major bleeding were observed in either group. Another randomized open-label study evaluated the comparative effectiveness of rivaroxaban DOAC with warfarin among 120 high-risk (defined by triple-positive aPL) APS patients with a mean follow up of 569 days.^\[[@R80]\]^ The primary outcomes were cumulative thrombotic events, major bleeding, and vascular mortality, which were noted to be significantly higher in the rivaroxaban group compared with warfarin (HR 7.4, 95% CI 1.7--32.9, *P* = 0.008) during interim analysis. Seven arterial thromboses and one venous thrombosis occurred in the rivaroxaban group whereas none occurred in the warfarin group. Considering the excessive risk and no apparent benefits of rivaroxaban among high-risk APS patients, this study was terminated early.^\[[@R80]\]^ The most recent trial, a randomized non-inferiority study published in October 2019, again did not demonstrate non-inferiority of rivaroxaban compared with warfarin as a secondary thrombosis prophylaxis agent.^\[[@R81]\]^ A slightly increased risk of arterial thrombosis was also observed (RR 19, 95% CI 1.1--321.9).^\[[@R81]\]^ There is one more ongoing randomized controlled trial (ASTRO-APS) evaluating DOAC use for APS secondary thrombosis prophylaxis.^\[[@R78]\]^ In summary, we do not currently have data to support the use of DOACs for thrombotic APS. Furthermore, there is evidence against the use of DOACs for secondary thrombosis prophylaxis among high-risk APS patients and especially any patient with a history of arterial manifestations (which is perhaps not surprising as DOACs are not approved for arterial indications in the general population). The reasons DOACs have failed to prevent recurrent thrombosis in APS remains unclear. Suboptimal dosing and uncontrolled anticoagulation intensity (none of the trials standardized anticoagulation intensity with anti-Xa factor activity) could be contributing factors. It is possible that these agents may eventually find a role in a subgroup of APS patients, but further study is certainly needed before that is the case.

In summary, moderate-intensity warfarin remains the primary strategy for secondary thrombosis prophylaxis among APS patients. LDA can also be added for patients with arterial thrombosis. For the subgroup of patients who develop thrombosis while on warfarin, alternative therapy with either LMWH or high-intensity warfarin can be considered. No randomized control data at this time support the use of DOACs among thrombotic APS patients, and DOACs should likely be avoided among high-risk APS patients unless the clinician is dealing with special circumstances.

Obstetric APS management
========================

Pregnancy management strategies for patients with aPL or APS are largely based on small trials, observational studies, and expert opinions. Here we will summarize current recommended treatment strategies and available evidence for five clinical APS related obstetric scenarios \[Table [4](#T4){ref-type="table"}\].

###### 

Obstetric management of APS.
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Asymptomatic aPL carriers
-------------------------

There are conflicting data regarding how to best manage those patients with persistently high-titer aPL who have never had pregnancy complications nor thromboses. Two randomized control trials and one retrospective observation of pregnant women with positive aPL, but without SLE did not show a difference in live birth rate with the use of LDA (defined as between 75 mg daily to 81 mg daily).^\[[@R82]--[@R84]\]^ One large randomized control trial of general high-risk pregnancy population (*n* = 1176), including advanced maternal age, smoking, hypertension, diabetes, low-level pregnancy related plasma protein A, and positive aPL, demonstrated that LDA resulted in significantly lower incidence of preterm preeclampsia.^\[[@R85]\]^ Current expert consensus recommends close monitoring of fetus and mother and considering LDA among asymptomatic aPL carriers with high-risk aPL profiles such as triple-positive aPL or persistently-positive LA.^\[[@R2],[@R75]\]^

aPL carriers with history of only recurrent first trimester pregnancy loss (no thrombosis history)
--------------------------------------------------------------------------------------------------

There are again conflicting data regarding how to best manage this group of women. Three RCTs suggested a significantly higher live birth rate with the combination of LDA and either LMWH or heparin.^\[[@R86]--[@R88]\]^ Two RCTs did not observe a difference in live birth rate between LDA alone and LDA and heparin combination.^\[[@R89],[@R90]\]^ A meta-analysis of all completed trials slightly favors the use of LDA with heparin/LMWH.^\[[@R3]\]^ Current recommendations endorse the addition of prophylaxis heparin/LMWH to LDA during pregnancy for those women with history of recurrent first-trimester pregnancy loss.^\[[@R75]\]^

aPL carriers with history of preeclampsia and/or second or third trimester pregnancy loss (no thrombosis history)
-----------------------------------------------------------------------------------------------------------------

One randomized control trial that evaluated 110 aPL-positive women with prior history of preeclampsia, placental abruption or late term pregnancy loss suggested that the combination of LDA and LMWH was associated with significantly lower rate of severe preeclampsia, placenta rupture, and low birth weight.^\[[@R91]\]^ Thus, it is recommended to use LDA and heparin/LMWH for this group of women during pregnancy.^\[[@R2],[@R75]\]^

aPL-positive women with history of thrombosis
---------------------------------------------

One small observational study of 20 pregnant women with thrombotic APS who received 100 mg daily aspirin and therapeutic LMWH showed a live birth rate of 91.3%.^\[[@R92]\]^ However, a high incidence of obstetric complications (preeclampsia 32.8% and premature delivery 42.9%) continued to be observed.^\[[@R92]\]^ It is well known that thromboembolic events among APS patients are significantly associated with a heightened future thrombosis risk and obstetric complications. The obstetric management consensus for aPL-positive women with prior thromboembolic events is to treat with a combination of LDA and therapeutic LMWH during pregnancy.^\[[@R48],[@R75]\]^

Postpartum management of aPL-positive women
-------------------------------------------

Even in general population, women during the postpartum period have a high risk of thrombosis.^\[[@R93]\]^ It is recommended that aPL-positive women who have never had thrombosis receive 6 weeks of prophylactic LMWH and women with APS who had history of thrombosis resume therapeutic anticoagulation (either warfarin or LMWH) immediately to prevent postpartum thrombosis.^\[[@R2],[@R48]\]^

In summary, obstetric APS management is complex and current recommendations are often based on lower-quality data and expert consensus. Patient education and counseling of obstetric risk is important. Treatment should be tailored based on an individual patient\'s aPL profile and obstetric and thrombotic history.

Potential new treatments/pathways for consideration
===================================================

APS is a complex multisystem disease. Recent pathophysiology studies have implicated many non-thrombotic pathways that contribute to various APS clinical manifestations. Traditional anticoagulation is often not effective for "non-criteria" APS clinical manifestations, which may often have their origins in the microvasculature. Here we summarize current evidence regarding treatment of APS with medications other than anticoagulants, and some emerging considerations in pharmacological management.

Rituximab
---------

B cells play an important role in APS pathogenesis. In vivo studies have shown that B cell inhibition prevents disease onset and prolongs survival in APS murine models.^\[[@R94]\]^ Several case reports have described the successful use of rituximab in APS patients with severe thrombocytopenia, hemolytic anemia, skin ulcers or necrosis, aPL nephropathy, and catastrophic APS.^\[[@R95]\]^ The RITAPS trial was a pilot open-label Phase II study that aimed to evaluate the safety of rituximab in adult primary APS patients.^\[[@R96]\]^ The findings suggested that rituximab is safe to use in APS patients and may be effective in controlling non-criteria manifestations such as thrombocytopenia, skin ulcers, and APS nephropathy.^\[[@R96]\]^

Eculizumab
----------

Complement activation plays an important role in APS pathogenesis. For example, murine studies have shown that complement activation is required for aPL-mediated fetal loss.^\[[@R20]\]^ In these models, complement inhibition prevents fetal growth restriction and can also reduce aPL-mediated thrombus formation.^\[[@R20],[@R94]\]^ Eculizumab is a humanized monoclonal antibody currently approved for treatment of atypical hemolytic uremic syndrome and paroxysmal nocturnal hematuria.^\[[@R97]\]^ The antibody binds to C5 and prevents C5 cleavage to C5a and C5b.^\[[@R97]\]^ Multiple case series have suggested its efficacy in treating refractory APS, CAPS, and SLE thrombotic microangiopathy.^\[[@R94],[@R97]\]^ There is an ongoing clinical trial aimed at evaluating the safety and tolerability of eculizumab among APS renal transplant patients and evaluating its effect on thrombosis prevention (ClinicalTrials.gov Identifier: NCT01029587).

Defibrotide and adenosine receptor agonists
-------------------------------------------

Defibrotide is a mixture of oligonucleotides derived from the controlled depolymerization of porcine intestinal mucosal DNA with antithrombotic, anti-ischemic, and anti-inflammatory activities. It binds to the vascular endothelium, modulates platelet activity, promotes fibrinolysis, decreases thrombin generation and activity, and reduces circulating levels of plasminogen activator inhibitor type 1 (PAI-1).^\[[@R98]--[@R102]\]^ It may also act as an adenosine receptor agonist and is thought to have particular affinity for receptors A1 and A2.^\[[@R103]\]^

A number of studies have suggested the potential efficacy of defibrotide in vascular disorders, including peripheral vascular disease, microvascular thrombotic states, and chemotherapy-related hemolytic uremic syndrome.^\[[@R104]--[@R106]\]^ Defibrotide was initially approved for the treatment of thrombophlebitis and as prophylaxis for deep vein thrombosis in Italy.^\[[@R104],[@R107]\]^ It has also been approved in the United States and Europe for treatment of severe hepatic veno-occlusive disease (sVOD) following high-dose chemotherapy and autologous bone marrow transplantation. Given its known functions as an endothelium-protective reagent and adenosine receptor agonist, defibrotide has been successfully used to treat at least one refractory CAPS patient.^\[[@R108]\]^ Tolerability of defibrotide appears to be acceptable with a relative lack of systemic anticoagulant activity, which could suggest a possible therapeutic advantage over other available treatments.^\[[@R109]\]^ More research seems warranted to probe the efficacy and safety of defibrotide in APS, especially in treatment-refractory microvascular disease and CAPS.

Other approaches
----------------

Coenzyme Q10 (CoQ10) plays an important role in the electron transport chain of the mitochondrial membrane, while adequate CoQ10 levels protect cells from protein oxidation and lipid peroxidation. Supplementation of CoQ10 has been trialed in patients with coronary artery disease, where it decreases the production of proinflammatory cytokines.^\[[@R110]\]^ One recent RCT evaluated the effect of ubiquinol (a reduced CoQ10 supplement) on prothrombotic and inflammatory mediators among APS patients.^\[[@R111]\]^ The study found that ubiquinol improved endothelial function and decreased monocyte expression of prothrombotic mediators among APS patients.^\[[@R111]\]^ No clinically significant side effects were observed in the ubiquinol-treated patients.^\[[@R111]\]^ The authors suggested that ubiquinol might complement current standard APS therapies.^\[[@R111]\]^ During the 2019 International Congress on Antiphospholipid Antibodies other potential therapeutic targets for APS, such as agents targeting plasma cells and interferons, were discussed ([http://icapaconference.com](http://icapaconference.com/)). Whether neutralization of antibody-producing plasma cells or interferon might mitigate criteria or non-criteria manifestations of APS awaits further study.

In summary, agents that target B-cell and complement activation have been used and evaluated clinically for the management of "non-criteria" APS manifestations such as thrombocytopenia, nephropathy, and thrombotic microangioapthy. More data are needed before any of these agents can be formally recommended. Recent advancements in our understanding of APS pathogenesis, particularly the role of NETosis in APS, may provide new pathways for targeted therapies that could change, and increasingly personalize, the management of APS.

In conclusion, APS is a complex thromboinflammatory syndrome with various clinical manifestations. Primary thrombosis prophylaxis should take an individualized risk stratification approach to make a personalized decision regarding the addition of LDA, HCQ, and/or statin. Moderate-intensity warfarin remains the primary strategy for secondary thrombosis prophylaxis among APS patients. DOACs should be avoided among triple-positive APS patients, especially those with history of arterial manifestations. Obstetric APS management should be tailored based on individual patient\'s aPL profile, and obstetric and thrombotic history. Pharmacological agents beyond anticoagulants can be considered for the management of "non-criteria" manifestations, though more data are needed.
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